Prelude Capital Management’s Astria Therapeutics ATXS Stock Holding History

Prelude Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-529,021	Closed	-$6.92M	–	1216
2025 Q4	$6.92M	Buy	+529,021	New	+$6.32M	0.51%	30
2016 Q1	–	Sell	-7	Closed	-$3K	–	1251
2015 Q4	$3K	Buy	+7	New	+$3.36K	﹤0.01%	1358

Prelude Capital Management's ATXS Position: Q1 2026 in Review

Prelude Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 529,021 shares — an estimated $6.92M sold.

Prelude Capital Management first reported a position in ATXS in Q4 2015 and held it in 2 quarters. The position peaked at $6.92M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Prelude Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 529,021 Astria Therapeutics shares in Q1 2026, an estimated $6.92M.
Prelude Capital Management first reported a position in Astria Therapeutics in Q4 2015 and held it in 2 quarters.
Prelude Capital Management's Astria Therapeutics position peaked at $6.92M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.